SAN
DIEGO, Jan. 10, 2025 /PRNewswire/ -- Expert
Systems, a hybrid AI enabled drug discovery and development
accelerator, announced a significant milestone in a development of
Traws Pharma, Inc. 's (NASDAQ: TRAW) H5N1 antiviral program. The
investigational drug, Tivoxavir Marboxil, has shown
encouraging results as a single-dose treatment for H5N1 avian
influenza, representing a potentially pivotal advance in addressing
this serious health challenge.
Tivoxavir Marboxil, an oral cap-dependent endonuclease
inhibitor, targets a highly conserved influenza protein,
demonstrating broad-spectrum efficacy against various flu strains,
including avian influenza. Preclinical studies have highlighted its
potent activity against drug-resistant and highly pathogenic bird
flu viruses, both in vitro and in vivo.
In a recent randomized, double-blind, placebo-controlled Phase 1
clinical trial, the safety, tolerability, and pharmacokinetics of
single ascending doses of Tivoxavir Marboxil were evaluated
in healthy, influenza-negative adult volunteers. The trial reported
no treatment-related adverse events. Notably, a single dose
maintained plasma drug levels above the effective concentration
(EC90) for over 23 days, indicating the potential for sustained
efficacy with a one-time administration.
Dr. Robert R. Redfield, Chief
Medical Officer for Traws Pharma and former Director of the U.S.
Centers for Disease Control and Prevention (CDC), commented: "The
spread of avian influenza in wild and domestic animal populations,
including mammals, brings increasing risk for adaptation to humans
and subsequent spread in the population. With increasing numbers of
human infections and recent reports of severe cases, we should be
alert to the rising potential for epidemic or pandemic spread of
bird flu."
Expert Systems has been instrumental in the ideation, design,
incubation, and support of this program, taking advantage of its
hybrid human and AI-based drug discovery, development and venture
studio startup services platform. This collaboration underscores
the effectiveness of integrating artificial intelligence with human
expertise and computer-aided drug design and business management,
to expedite the development of innovative therapies.
"The success of Tivoxavir Marboxil underscores the
transformative potential of combining artificial intelligence with
human expertise to tackle urgent global health challenges," said
Tudor Oprea, Chief Executive Officer of Expert Systems. "We are
excited to support Traws Pharma in bringing this innovative flu
treatment closer to market."
With the completion of Phase 1 trials, plans are underway to
initiate Phase 2 efficacy studies in the first half of 2025. This
brings Tivoxavir Marboxil closer to becoming a viable
treatment option for H5N1 bird flu, addressing a critical need in
global health.
About Traws Pharma
Traws Pharma, Inc. is a
clinical-stage biopharmaceutical company dedicated to developing
oral small molecule therapies for respiratory viral diseases and
cancer. Leveraging expertise in small molecule chemistry,
artificial intelligence, and streamlined development processes,
Traws Pharma focuses on creating innovative medicines targeting
critical health threats, including drug-resistant influenza viruses
and avian flu.
https://www.trawspharma.com/
About Expert Systems
Expert Systems is a drug
discovery and development accelerator and leader in
computer-enabled discovery and development platforms, committed to
advancing the development of innovative therapies that address
critical unmet medical needs. Combining advanced machine learning
algorithms with broad domain expertise, Expert Systems accelerates
the development of life-saving treatments in infectious diseases,
oncology, CNS, immunology and cardiometabolic diseases. The
company's innovative approach is reshaping the future of
therapeutics.
https://www.expertsystems.inc/
Media Contact:
Bill Farley
Chief Business Officer
bfarley@expertsystems.inc
View original content to download
multimedia:https://www.prnewswire.com/news-releases/expert-systems-and-traws-pharma-report-breakthrough-in-h5n1bird-flu-antiviral-program-302348431.html
SOURCE Expert Systems, Inc.